Raymond James Stays Sidelined on Sarepta (SRPT) Citing 'heavily eclipsed market opportunity' and 'binary risk heading into EMBARK'
Tweet Send to a Friend
Raymond James analyst Danielle Brill reiterated a Market Perform rating and {REMOVEPT} price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
